NEW YORK, Jan 3 (Reuters) – Botox-maker Allergan Plc
on Wednesday said it plans to cut over 1,000 jobs, more than 5
percent of its workforce, and eliminate an additional 400
currently open positions, as it works to cut costs in the face
of new competition for its second most important drug, dry-eye
treatment Restasis.

Read More At Article Source | Article Attribution